Prosonix is an emerging pharmaceutical company developing a portfolio of enhanced respiratory medicines (mono and combination therapies) that could revolutionise the multi-billion dollar global market for inhaled therapies.

Its current development programmes include:

• PSX1001, a drug-only version of fluticasone propionate, a potent inhaled corticosteroid monotherapy for asthma in metered dose inhaler (MDI);

• PSX1002, a drug-only version of glycopyrrolate, a long acting muscarinic antagonist for COPD in MDI, and

• PSX2000 Series, a potentially revolutionary approach to combination therapy

Prosonix' pipeline is underpinned by its world leading expertise in pharmaceutical particle engineering and its unique, proprietary DISCUS® and UMAX® technologies. These capabilities enable Prosonix to develop ‘smart' respiratory drug particles that are specifically designed to target the optimum site of action in the lung, precisely and consistently, to gain maximum clinical effect.

By controlling particle size, shape and form Prosonix can develop superior drug formulations, offering more accurate dosing and enabling the use of simple, cost-effective MDI and dry powder inhaler devices.